-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the marketing application of aflibercept intraocular injection solution submitted by Qilu Pharmaceutical under the new drug category 3.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
Source: CDE official website
Aflibercept is a VEGF inhibitor developed by Bayer/Regeneron, which can inhibit vascular proliferation and reduce vascular permeability by inhibiting the signaling pathway mediated by VEGF-A, VEGF-B and placental growth factor (PLGF).
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
Bayer's aflibercept intraocular injection solution was approved to enter the domestic market in February 2018, and was included in the national medical insurance category B catalog through negotiation in 2019
.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
Sales of aflibercept intraocular injection solution in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, no aflibercept biosimilars have been approved in China, but many pharmaceutical companies have deployed them.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Some biological drugs deployed by Qilu Pharma
Source: Mi intranet database
Biological medicine is the key area of Qilu Pharma
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
Source: Minet database, CDE official website, etc.
Note: The statistics are as of May 5, if there are any omissions, please correct me!
Recently, the marketing application of aflibercept intraocular injection solution submitted by Qilu Pharmaceutical under the new drug category 3.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
Source: CDE official website
Aflibercept is a VEGF inhibitor developed by Bayer/Regeneron, which can inhibit vascular proliferation and reduce vascular permeability by inhibiting the signaling pathway mediated by VEGF-A, VEGF-B and placental growth factor (PLGF).
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
Bayer's aflibercept intraocular injection solution was approved to enter the domestic market in February 2018, and was included in the national medical insurance category B catalog through negotiation in 2019
.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
Sales of aflibercept intraocular injection solution in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, no aflibercept biosimilars have been approved in China, but many pharmaceutical companies have deployed them.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Some biological drugs deployed by Qilu Pharma
Source: Mi intranet database
Biological medicine is the key area of Qilu Pharma
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
Source: Minet database, CDE official website, etc.
Note: The statistics are as of May 5, if there are any omissions, please correct me!
Recently, the marketing application of aflibercept intraocular injection solution submitted by Qilu Pharmaceutical under the new drug category 3.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
3 was accepted by the CDE, and it was the first aflibercept biosimilar to be reported for production in China
.
According to data from Minet.
com, the sales of aflibercept intraocular injection solution in public medical institutions in China will exceed 600 million yuan in 2021, a year-on-year increase of nearly 60%
.
Source: CDE official website
Aflibercept is a VEGF inhibitor developed by Bayer/Regeneron, which can inhibit vascular proliferation and reduce vascular permeability by inhibiting the signaling pathway mediated by VEGF-A, VEGF-B and placental growth factor (PLGF).
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
sex
.
Aflibercept has been approved in many countries and regions for the treatment of vision caused by neovascular age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema, and pathological myopic choroidal neovascularization.
damage,
etc.
According to Regeneron’s financial report, Aflibercept’s global sales in 2021 will exceed $9 billion
.
Bayer's aflibercept intraocular injection solution was approved to enter the domestic market in February 2018, and was included in the national medical insurance category B catalog through negotiation in 2019
.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
hospital hospital hospital.
According to data from Minet.
com, in recent years, the terminal sales of aflibercept intraocular injection solution in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have increased year by year, and will exceed 6 in 2021.
billion, a year-on-year increase of nearly 60%
.
Sales of aflibercept intraocular injection solution in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, no aflibercept biosimilars have been approved in China, but many pharmaceutical companies have deployed them.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Among them, Qilu Pharmaceutical's products have been reported for production, the first in China
.
In addition, Shandong Boan Bio's LY09004 and Maiwei Bio's 9MW0813 are all in phase III clinical trials
.
Some biological drugs deployed by Qilu Pharma
Source: Mi intranet database
Biological medicine is the key area of Qilu Pharma
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
.
In terms of class 1 new drugs, recombinant human thrombopoietin-Fc fusion protein for injection and VB4-845 injection have entered Phase III clinical trials; in terms of biosimilars, bevacizumab biosimilars, recombinant human Biosimilars of oocyte-stimulating hormone have been approved, and biosimilars of denosumab and roprestim have been declared for marketing
.
Source: Minet database, CDE official website, etc.
Source: Minet database, CDE official website, etc. Note: The statistics are as of May 5, if there are any omissions, please correct me!
